Evotec SE

3.15
0.18 (6.06%)
At close: Apr 08, 2025, 11:25 AM

Company Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.

It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals.

The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.

Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE
Evotec SE logo
Country DE
IPO Date Feb 5, 2004
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 5,007
CEO Dr. Cord Dohrmann Ph.D.

Contact Details

Address:
Essener Bogen 7
Hamburg,
DE
Website https://www.evotec.com

Stock Details

Ticker Symbol EVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001412558
CUSIP Number 30050E105
ISIN Number US30050E1055
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Cord Dohrmann Ph.D. Chief Scientific Officer & Member of Management Board

Latest SEC Filings

Date Type Title
Nov 29, 2024 6-K Filing
Nov 22, 2024 6-K Filing
Nov 15, 2024 6-K Filing
Nov 08, 2024 SC 13D Filing
Nov 06, 2024 6-K Filing
Aug 14, 2024 6-K Filing
Aug 14, 2024 20-F Filing
Aug 06, 2024 6-K Filing
Jun 10, 2024 6-K Filing
May 22, 2024 6-K Filing